08048035996
Respiratory NEOSURF 3ml Injection trusted to Canada - Toronto | Phoenix Exim | Global Exporter

1. General Information

NEOSURF 3 mL Injection is a bovine lipid extract surfactant preparation used in neonatal intensive care. It is designed to replace or supplement deficient lung surfactant in premature newborns with Neonatal Respiratory Distress Syndrome (NRDS). NEOSURF contains natural phospholipids and surfactant-associated proteins and is manufactured by Cipla Ltd.

The product is supplied as a sterile suspension in a 3 mL single-use vial and is intended for intratracheal administration only, following establishment of an endotracheal airway.

Phoenix Exim, a medicine exporter from Nagpur, India, can provide information regarding pharmaceutical supply and international export of NEOSURF 3 mL to markets including the USA, UK, Australia, Singapore, Canada, South Korea and UAE, subject to applicable import and regulatory requirements.

2. Product Information

  • Brand: NEOSURF
  • Strength: 27 mg phospholipids/mL
  • Pack size: 3 mL vial
  • Active substance: Bovine lipid extract surfactant
  • Dosage form: Sterile suspension
  • Route: Intratracheal instillation only
  • Manufacturer: Cipla Ltd.
  • Therapeutic class: Lung surfactant
  • Storage: Refrigerated, generally 2°C–8°C; do not freeze.

The 3 mL presentation contains approximately 81 mg of phospholipids, consistent with official Indian regulatory records.

3. Uses of NEOSURF 3 mL Injection

NEOSURF is primarily used for the treatment of Neonatal Respiratory Distress Syndrome (NRDS) in premature infants whose lungs do not produce enough natural surfactant.

It may be used as part of neonatal respiratory care to:

  • Restore deficient pulmonary surfactant activity
  • Reduce alveolar surface tension
  • Improve lung compliance
  • Support more effective gaseous exchange
  • Help prevent alveolar collapse during expiration

4. Benefits of NEOSURF

When appropriately administered under specialist neonatal care, NEOSURF may help:

  • Restore surfactant function in immature lungs.
  • Improve pulmonary mechanics and lung compliance.
  • Reduce alveolar surface tension.
  • Support oxygenation and gaseous exchange.
  • Improve respiratory function in premature infants with NRDS.

The medicine is administered directly into the airway because the therapeutic objective is to deliver surfactant to the infant's lungs.

5. Side Effects

Surfactant administration can sometimes cause complications, particularly around the time of intratracheal administration. These may include:

  • Transient oxygen desaturation
  • Bradycardia
  • Changes in blood oxygenation
  • Airway obstruction or reflux of the suspension
  • Need for temporary adjustment of ventilator settings
  • Rare respiratory complications

The infant should therefore be continuously monitored by appropriately trained neonatal healthcare professionals during and after administration.

6. Common Side Effects / Administration-Related Reactions

Possible short-term reactions during administration can include:

  • Temporary reduction in oxygen saturation
  • Changes in heart rate
  • Changes in blood pressure
  • Airway-related complications
  • Transient changes in ventilation requirements

Because NEOSURF is used in critically ill premature infants, some events may also be associated with the underlying respiratory condition rather than the medicine itself. The official product information should be consulted for the complete adverse-reaction profile.

7. How to Use NEOSURF

NEOSURF should not be self-administered. It is intended for intratracheal instillation by qualified healthcare professionals after an endotracheal airway has been established.

The manufacturer's product information gives a recommended dose of 5 mL/kg at 27 mg phospholipids/mL, equivalent to 135 mg phospholipid/kg. Up to three subsequent doses may be given within the first five days of life when clinically indicated.

The actual dose, timing and repeat-dose requirement must be determined by the neonatologist according to the infant's clinical condition and the approved product information.

8. How NEOSURF Works

Premature infants may have insufficient pulmonary surfactant, causing increased surface tension inside the alveoli. This can make the alveoli difficult to keep open and interfere with normal gaseous exchange.

NEOSURF supplies natural bovine-derived phospholipids and surfactant-associated proteins, including SP-B and SP-C. After intratracheal administration, the surfactant spreads across the alveolar air-fluid interface, reducing surface tension and helping stabilize the alveoli. This can improve lung compliance and gaseous exchange.

9. Safety Advice

  • Use only under specialist medical supervision.
  • NEOSURF is intended for intratracheal use only.
  • Do not inject it intravenously, intramuscularly or subcutaneously.
  • Administration requires an established endotracheal airway.
  • Monitor oxygenation, heart rate, respiratory status and ventilation closely during administration.
  • Use each vial only as directed; the product information describes the vials as single-use.
  • Store refrigerated according to the approved product labeling and do not freeze.
  • The product should be handled by trained neonatal healthcare professionals.
  • Always follow the manufacturer's prescribing information and the treating neonatologist's instructions.

10. Frequently Asked Questions (FAQs)

Q1. What is NEOSURF 3 mL Injection used for?
NEOSURF is a pulmonary surfactant used primarily for treating Neonatal Respiratory Distress Syndrome in premature infants.

Q2. What is the active ingredient in NEOSURF?
It contains bovine lipid extract surfactant, including phospholipids and surfactant-associated proteins.

Q3. How much phospholipid does NEOSURF contain?
The formulation contains 27 mg of phospholipids per mL.

Q4. Is NEOSURF given by intravenous injection?
No. NEOSURF is specifically intended for intratracheal instillation after an endotracheal airway has been established.

Q5. Can NEOSURF be administered at home?
No. It is a specialized neonatal medicine requiring administration and monitoring by trained healthcare professionals.

Q6. How should NEOSURF be stored?
It should generally be refrigerated at 2°C–8°C and should not be frozen, according to product information.

Q7. Who manufactures NEOSURF?
NEOSURF is manufactured/marketed by Cipla Ltd.

Q8. Is NEOSURF suitable for every newborn with breathing problems?
No. Its use depends on the diagnosis, gestational age, respiratory status and clinical assessment by a neonatologist.

11. Substitutes / Alternative Surfactant Products

Possible alternative pulmonary surfactants include:

  • Curosurf (poractant alfa)
  • Survanta (beractant)
  • Alveofact
  • Other approved neonatal pulmonary surfactant preparations

These products are not necessarily interchangeable on a milligram-for-milligram or volume-for-volume basis. Their composition, concentration, dosing and approved indications can differ. Indian regulatory records list products such as Curosurf, Alveofact and Neosurf among pulmonary surfactants.

A neonatologist should select the appropriate surfactant according to the infant's clinical requirements and local approved guidelines.

12. SEO Keywords

  • NEOSURF 3 mL Injection exporter from India
  • NEOSURF 3 mL Injection supplier
  • NEOSURF 3 mL pharmaceutical exporter
  • NEOSURF bovine lipid extract surfactant
  • NEOSURF 27 mg injection
  • NEOSURF 3 mL vial supplier
  • NEOSURF neonatal surfactant exporter
  • NEOSURF injection for NRDS
  • Neonatal respiratory distress syndrome surfactant
  • Bovine lung surfactant injection supplier
  • Pulmonary surfactant exporter India
  • Neonatal medicine exporter from Nagpur
  • Pharmaceutical exporter Nagpur India
  • NEOSURF Cipla supplier India
  • NEOSURF 3 mL export supplier
  • NEOSURF injection wholesale supplier
  • Genuine NEOSURF 3 mL supplier
  • NEOSURF surfactant medicine exporter
  • NEOSURF supplier to USA
  • NEOSURF supplier to UK
  • NEOSURF supplier to Australia
  • NEOSURF supplier to Singapore
  • NEOSURF supplier to Canada
  • NEOSURF supplier to South Korea
  • NEOSURF supplier to UAE
  • Neonatal pulmonary surfactant exporter India
  • Premature infant surfactant medicine supplier
  • NRDS treatment surfactant supplier
  • Hospital neonatal medicine exporter
  • Critical care pharmaceutical exporter India
Aug 21st, 2026 3:09 PM

Keywords